Microfluidic DNA-based potassium nanosensors for improved dialysis treatment
- 144 Downloads
Patients with end-stage renal disease (ESRD) have failed kidney function, and often must be treated with hemodialysis to extend the patient’s life by artificially removing excess fluid and toxins from the blood. However, life-threatening treatment complications can occur because hemodialysis protocols are adjusted infrequently, as opposed to the kidneys which filter blood continuously. Infrequent blood tests, about once per month on average, are used to adjust hemodialysis protocols and as a result, patients can experience electrolyte imbalances, which can contribute to premature patient deaths from treatment complications, such as sudden cardiac death. Since hemodialysis can lead to blood loss, drawing additional blood for tests to assess the patient’s kidney function and blood markers is limited. However, sampling multiple drops of blood per session using a microfluidic device has the potential to reduce not only the amount of blood drawn and avoid unnecessary venipuncture, but also reduce costs by limiting medical complications of hemodialysis and provide a more comprehensive assessment of the patient’s health status in real time.
We present preliminary proof-of-concept results of a microfluidic device which uses DNA-based fluorescence nanosensors to measure potassium concentration in a flowing solution. In a matter of minutes, the flowing potassium solution reduced the fluorescence intensity of the nanosensors to a steady-state value.
These proof-of-concept results demonstrate the ability of our DNA-based nanosensors to measure potassium concentration in a microfluidic device. The long-term goal is to integrate this technology with a device to measure potassium and eventually other blood contents multiple times throughout a hemodialysis session, enabling protocol adjustment similar to a healthy kidney.
KeywordsPotassium sensor DNA nanosensor G-quadruplex Microfluidics Fluorescence oligonucleotide
In the USA alone, more than 726,000 patients suffer from kidney failure with more than 124,000 new yearly diagnoses and 28% mortality rate . More than 71% of kidney failure patients require frequent hemodialysis to filter their blood artificially, and without dialysis the patient median survival time is only several weeks . The goal of hemodialysis is to remove waste from the blood and maintain equilibrium of body fluids, functions naturally performed by the kidneys. During hemodialysis sessions, the patient’s blood is pumped from their arm into a machine which uses a dialyzer to filter the blood before it is infused back into the patient. The dialyzer contains two chambers, one for blood and one for dialysate, a solution of water, electrolytes, and salts. Toxins from the blood are diffusively transported across a semi-permeable membrane into the dialysate to provide artificial filtration that replaces the function of the kidneys.
In contrast to the kidneys, which function and adjust electrolytes continuously, adjustment of hemodialysis protocols and the dialysate is dependent on each dialysis center. Dialysates are adjusted infrequently and often prepared generically using a uniform concentration of electrolytes without consideration of each individual patient’s blood electrolyte concentration. Blood electrolyte concentrations can be assessed by blood tests; however, these are costly, carry risks such as blood loss, anemia, hematoma, and infection, and can be impractical if required for each of the multiple weekly dialysis sessions [3, 4, 5, 6]. Consequently, electrolyte levels, including potassium, are assessed infrequently and can contribute to blood electrolyte imbalances [7, 8, 9]. The leading cause of mortality in hemodialysis patients is sudden death due to cardiac arrest, which accounts for 45% of deaths [10, 11, 12, 13]. Since potassium is the primary ion regulating cardiac repolarization, potassium imbalances have been hypothesized to trigger arrhythmias and contribute to sudden cardiac arrest in hemodialysis patients [11, 14]. Hence, monitoring potassium levels in hemodialysis patients is paramount.
Presently, blood electrolyte levels of dialysis patients are assessed with UV absorbance , optical [16, 17], or electrochemical [18, 19, 20] based assays that require large blood samples. Results commonly require 24 h or longer before they are received. More recently, molecular fluorescence-based techniques have been explored in research laboratory settings to measure potassium in solution [21, 22]. Molecular fluorescence-based assays have the potential of higher specificity and sensitivity than the more popular electrochemical (potentiometric) and electrical-impedance methods . Advances in molecular sensing techniques have led to the development of novel DNA-based oligonucleotide nanosensors that can measure cations using G-quadruplex structures, where four guanines in a DNA strand encapsulate a monovalent ion in a plane . While the physiological function of G-quadruplex structures is likely involved in DNA replication, transcription, and repair , with the addition of fluorescence dyes to the end of the GGGG sites, direct fluorescence measurement of electrolytes is possible . G-quadruplex has been previously used for potassium ion detection. More recently, a selective potassium ion G-quadruplex sequence has been identified, with little interference from competitive ions at physiological concentrations .
In this study, based on the selective G-quadruplex sequence, we developed a first-generation microfluidic-based DNA nanosensor to measure potassium in an aqueous solution with the ultimate goal of measuring electrolytes in blood plasma at the point of care. In the device, fluorescence and quenching dyes FAM and DABCYL, respectively, are integrated into scaffold oligonucleotides rendering the DNA nanosensor. The DNA nanosensor is immobilized on the glass bottom of the device. Upon excitation, the absence of potassium results in light emission, while interaction between potassium and the DNA nanosensor leads to quenching of the fluorophore. Using the nanosensor, measuring serum electrolyte levels with a small sample volume in a point-of-care microfluidic device presents an opportunity to reduce clinical errors that can occur prior to sample analysis due to labeling, collection, and transport mishaps , in addition to reducing the amount of blood loss experienced by the patient. Furthermore, a microfluidic device allows for more frequent monitoring of a patient’s electrolyte levels by measuring multiple drops of blood per hemodialysis session, providing a more comprehensive assessment of the patient’s health.
Preparation of oligonucleotide sample for DNA nanosensor
Fluorescence spectrum measurement
A static fluorescence assay was performed with a fluorescence spectrometer (HORIBA, PTI fluorescence system) to test the function of the DNA nanosensor for K+ sensing at room temperature. The DNA nanosensor at a concentration of 1 µM was used and K+ was added at concentrations of 0, 1 μM, 1 mM, and 10 mM to measure the change in fluorescence intensity. Potassium chloride (KCl) was the source of K+ for all experiments.
DNA nanosensor concentration sensitivity
A DNA nanosensor concentration assay was performed with a fluorescence spectrometer (HORIBA, PTI fluorescence system) in real time to further analyze the relationship of the DNA nanosensor concentration for constant K+ concentrations at room temperature. The DNA nanosensor concentrations of 0, 1, 5, 10, 16.6 and 33.3 µM were used as K+ was added sequentially. K+ concentrations investigated were 0, 1, 5, and 25 mM.
DNA nanosensor ion selectivity measurement
To enhance the selectivity of the nanosensor, EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid) at a concentration of 3 mM was added to samples containing K+, Na+, and Ca2+ and incubated at room temperature for 15 min to abrogate the interference of calcium ions . The 0.5 μM DNA nanosensor solution was then added and incubated for 2 h at room temperature, followed by fluorescent measurements. A fluorescence spectrometer was used to measure the fluorescence intensity of samples with and without EGTA. Samples were diluted by a factor of 10 and 100 times from physiological concentrations.
Surface treatment of glass slides
Standard 75-mm × 38-mm glass slides (Thermo Fisher Scientific) were immersed in ethanol for 15 min for cleaning and dried with filtered nitrogen gas. The slides were exposed to oxygen plasma (Harrick Plasma, Plasmaflo) for 1 min to create OH− groups on the glass surface. The modified slides were immediately immersed in a 1% v/v (3-glycidyloxypropyl)trimethoxysilane solution for 20 min to allow the epoxy-silane to bond to the OH− groups on the slides. The treated glass slides were washed using deionized water, and dried quickly using filtered nitrogen gas.
DNA nanosensor concentration sensitivity on glass slide
DNA nanosensors were coated at different concentrations of 0, 0.1, 1, 5, 10, 15, 20, and 25 µM on treated glass slides. The DNA nanosensor fluorescence signal was measured at 37 °C using epifluorescence microscopy. Images were acquired immediately after coating and the fluorescence intensity for each concentration was determined using ImageJ software (NIH, Bethesda, MD).
Fabrication of DNA-based nanosensor microfluidic device
The microfluidic device was fabricated using standard photolithography and soft lithography protocols. A master mold with a design of five parallel microfluidic channels was created using a silicon wafer. Polydimethylsiloxane (PDMS), mixed with a base/agent ratio of 10:1, was poured to completely cover the device mold. The PDMS was cured for 24 h at room temperature followed by 24 h at 65 °C to minimize the effects of PDMS shrinking. The PDMS device was cut from the mold using a razor blade. The PDMS device was then bonded to the silane-treated glass slides by exposing the PDMS device and treated glass slide to oxygen plasma for 1 min in a plasma cleaner (Harrick Plasma, Plasmaflo), pressing the PDMS device onto the treated glass slides with even pressure, and heating the assembled device at 65 °C for 30 min.
The device channels were filled with a 25 µM amino-modified DNA nanosensor solution using a syringe and incubated overnight at room temperature to allow the DNA nanosensors to immobilize through amine–epoxy binding . Afterwards, the channels were washed ten times with buffer solution (PB + MgCl2) to remove excess unbonded oligonucleotides. The completed microfluidic device, functionalized with the DNA nanosensors, was analyzed at room temperature and stored at 4 °C until used. A syringe pump (PHD Ultra, Harvard Apparatus) was connected to the device inlet and infused at a rate of 0.02 mL/h and yielded a shear rate of 91 s−1. These experiments were conducted at 37 °C and a minimum of three samples were analyzed for statistical significance.
DNA nanosensor formation
Fluorescence spectrum measurement
DNA nanosensor concentration sensitivity
Immobilized DNA nanosensor concentration sensitivity
Microfluidic device experiment
DNA nanosensor ion selectivity measurement
To address the moderate selectivity of Ca2+ by the DNA nanosensors, the experiments from Fig. 8a were repeated by including or excluding EGTA, a calcium chelator. As a control, the DNA nanosensor fluorescence intensity was measured in the absence of Na+, Ca2+, and K+ ions, and the intensity did not change with the addition of EGTA (Fig. 8c). Diluting the physiologically relevant Na+, Ca2+, and K+ cation concentration by 100 times decreased fluorescence intensity by 17.4%, while adding EGTA to this cation concentration decreased the fluorescence signal by 15.2%. Although similar in trend, a slightly larger effect due to EGTA was observed when the cation concentration was diluted by ten times yielding a 23.8% and 20% decrease in fluorescence intensity without and with EGTA, respectively. However, the greatest effect due to EGTA was observed at physiologically relevant cation concentrations. Adding 140 mM Na+, 2.4 mM Ca2+, and 10 mM K+ decreased the fluorescence intensity by 44.8%, while the addition of EGTA yielded a smaller decrease of 32.6%.
Importantly, when adding Na+, Ca2+, or K+ independently at the corresponding physiological concentrations, the DNA nanosensor clearly shows greater selectivity for K+ (Fig. 8d). The presence of 10 mM K+ alone decreased the fluorescence intensity by 32.8%, while adding all three cations simultaneously, decreased the signal by 44.8%. However, addition of EGTA to the solution with all three cations at approximately physiological concentrations decreased the fluorescence signal only by 32.6%, completely abrogating the effects of Ca2+ as shown at the peak wavelength of 518 nm. The value of 32.6% with all three cations and EGTA is comparable to the 32.8% percent intensity decrease with K+ alone, demonstrating that the DNA nanosensor can be used for selective K+ detection in the presence of EGTA.
To the best of our knowledge, these are the first sets of experiments to demonstrate a simple proof-of-concept microfluidic device to measure potassium in a flowing solution using DNA-based G-quadruplex nanosensors. Low flow rate laminar flows were used to infuse the channels . However, higher flow rates (data not shown) can be employed, yielding much faster fluorescence-quenching rates. In these experiments, a homogeneous solution was used. In a heterogeneous solution like blood, pulsatile flow with a retrograde component can be employed to promote mixing, ensuring that a uniform concentration of electrolytes interacts with the K+ DNA nanosensors.
These experiments were designed to demonstrate the validity of point-of-care potassium-measuring devices for potential future use at the point of care for hemodialysis patients. The concentrations of 5 mM and 7 mM KCl tested in the buffer solution match physiological potassium blood concentration levels, and are relevant to hemodialysis patients [13, 29, 30]. Future studies can be conducted to optimize the G-quadruplex potassium nanosensors to reduce the influence from serum molecules that may alter the signal and more accurately measure physiological potassium concentrations in whole blood. It has been previously demonstrated that an optimized G-quadruplex sequence can measure potassium selectively in blood, without interference from competitive ions at physiological concentrations . To demonstrate selectivity, our study used EGTA to abrogate the influence of calcium, which is completely feasible for clinical practice since calcium chelators are routinely used to inhibit coagulation during blood draws .
The novelty in this research arises from being able to use a lab-on-a-chip device that, if mass produced, can potentially cost less than current techniques and can measure molecules in blood quickly with high accuracy and with less blood volume required . In contrast, the current procedure is to draw blood from a patient once a month on average, send it to a laboratory and wait at least 24 h for the blood test results . Although this novel technology has the potential of being less expensive, the most important benefit is that the hemodialysis session can be modified instantaneously for each patient, transforming traditional hemodialysis to personalized medical therapy, where the blood-filtering needs of each patient are fine-tuned similar to the physiological kidney function. If key electrolytes like potassium could be monitored more efficiently to provide an individual profile for each patient, treatments could be more personalized and complications such as sudden cardiac death may be decreased.
We present proof-of-concept results for a microfluidic lab-on-a-chip device with external dimensions less than 2 cm that can quickly and accurately measure potassium using a minute amount of fluid. Our device utilizes novel DNA-based fluorescence oligonucleotide nanosensors to detect the presence of potassium flowing through a microfluidic channel, as an initial proof-of-concept for a lab-on-a-chip point-of-care device. After exposing the lab-on-a-chip nanosensor to potassium for approximately 4 min, a decrease in fluorescence signal was observed compared to control cases with buffer. Other commercially available devices require larger samples of blood and 24 h of turnaround time to receive results, a burden that can be avoided using a microfluidic device. This device would need further optimization to enhance uniform binding to a surface and improve sensitivity and selectivity before being considered in the clinics. Eventually, this device can be integrated with routine hemodialysis sessions to measure blood contents multiple times throughout a hemodialysis session, enabling protocol adjustment similar to a healthy kidney, which is presently unavailable. Sampling multiple drops of blood per session can reduce costs by limiting medical complications, avoid unnecessary venipuncture, and provide a real-time assessment of the patient’s health. This lab-on-a-chip device may allow hemodialysis centers to provide personalized medicine to patients, potentially reducing mortality rates and increasing quality of life.
We thank Dr. Melissa D. Sánchez for constructive criticism.
AFS, BZ, MY, and JMJ conceived and designed the experiments; AFS, BZ, and JMJ performed the experiments; AFS, BZ, and JMJ analyzed the data; MY and JMJ contributed reagents/materials/analysis tools; AFS and JMJ wrote the paper. All authors read and approved the final manuscript.
This work was supported in part by the NIH National Heart, Lung, and Blood Institute (NHLBI) Grant K25 HL107617 (to J. M. Jiménez).
Consent for publication
All the authors of the paper approved the publication of the article.
The authors declare that they have no competing interests.
- 5.Wizemann V, Buddensiek P, de Boor J, Grebe S, Schütterle G. Gastrointestinal blood loss in patients undergoing maintenance dialysis. Kidney Int Suppl. 1983;16:S218–20.Google Scholar
- 6.Conrad ME. Iron deficiency anemia. New York: Films Media Group; 2013.Google Scholar
- 9.Al-Saffar A-MH. Pre and post haemodialysis: the effect of electrolyte imbalance on ECGs of patients with end stage renal disease. Med J Babylon. 2011;8:221–9.Google Scholar
- 18.Gotch F, Evans M, Metzner K, Westphal D, Polaschegg H. An on-line monitor of dialyzer Na and K flux in hemodialysis. ASAIO Trans. 1990;36:M359–61.Google Scholar
- 19.Burnett RW, et al. Recommendations for measurement of and conventions for reporting sodium and potassium by ion-selective electrodes in undiluted serum, plasma or whole blood. Clin Chem Lab Med. 2000;38:1065–71.Google Scholar
- 20.Cowell DC, et al. Sodium and potassium ion selective electrodes: a review of theory and calibration. Med Lab Sci. 1985;42:252–61.Google Scholar
- 33.Day C. Haemodialysis blood results. Queen Elizabeth Hospital Birmingham, NHS Foundation Trust; 2017. https://www.uhb.nhs.uk/Downloads/pdf/PiHaemodialysisBloodResults.pdf
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.